Welcome to our dedicated page for Cybin news (Ticker: CYBN), a resource for investors and traders seeking the latest updates and insights on Cybin stock.
Cybin Inc. (CYBN) is a clinical-stage biopharmaceutical leader advancing novel psychedelic-based therapies for mental health conditions. This dedicated news hub provides investors and researchers with essential updates on the company's progress in developing innovative treatment solutions.
Access timely reports on clinical trial milestones, regulatory developments, and strategic partnerships that shape Cybin's research pipeline. Our curated collection includes official press releases detailing advancements in deuterated compound research, intellectual property achievements, and collaborative neuroscience initiatives.
Key updates cover FDA designations, preclinical study results, and patent filings that demonstrate Cybin's scientific rigor in psychedelic therapeutics development. The resource serves as a centralized tracking point for material events influencing the company's position in mental health innovation.
Bookmark this page for structured access to verified information about Cybin's therapeutic candidates and operational developments. Check regularly for objective updates on progress within the regulated biopharmaceutical research landscape.
Cybin has appointed Dr. Atul Mahableshwarkar as Senior Vice President of Clinical Development. With extensive experience in drug development and psychiatry, he will lead the CYB003 program, Cybin's deuterated psilocybin analog, which has FDA Breakthrough Therapy Designation for major depressive disorder. Dr. Mahableshwarkar’s expertise is expected to accelerate Cybin’s clinical trials, including the imminent Phase 3 study of CYB003 and Phase 2 study of CYB004 for Generalized Anxiety Disorder. His background includes global Phase 3 program management and regulatory submissions, which could be pivotal for Cybin’s growth.
Cybin, a clinical-stage biopharmaceutical company, will participate in significant events on June 5-8, 2024. Chief Medical Officer Amir Inamdar will discuss marketing approval and access pathways for psychedelics at two panels. Ellen James, Director of Clinical Development, will present research on SPL026 (DMT fumarate) combined with SSRIs for treating Major Depressive Disorder. Cybin's advancements in CYB003 and CYB004 for mental health treatment will also be highlighted, including the recent FDA Breakthrough Therapy Designation for CYB003 and positive Phase 2 trial results.
Cybin, a clinical-stage biopharmaceutical company, announced that CEO Doug Drysdale will participate in a virtual fireside chat at the Alliance Global Partners Healthcare Company Showcase on May 21, 2024. The presentation will be webcast live at 12:40 p.m. ET and will later be available on Cybin’s investor relations website. The company is focused on developing innovative psychedelic treatments for mental healthcare.
Cybin Inc., a clinical-stage biopharmaceutical company, recently secured a U.S. $150 million funding round to support its clinical programs CYB003 and CYB004. The company received FDA Breakthrough Therapy Designation for CYB003 in Major Depressive Disorder (MDD) and plans to start a Phase 3 study in mid-2024. Additionally, Phase 2 results for CYB004 in Generalized Anxiety Disorder (GAD) are expected in Q4 2024. Cybin emphasizes its commitment to revolutionizing mental healthcare through innovative psychedelic-based treatments.
FAQ
What is the current stock price of Cybin (CYBN)?
What is the market cap of Cybin (CYBN)?
